Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- CSIMC Continues to Fire Barbs at “Precursor Premium” Despite Industry Appeal
December 10, 2013
- Mr Umeda of PhRMA Opposes Proposal to Revise Foreign Average Price Adjustment Rule
December 10, 2013
- JGA President Prefers 60% Rule for NHI Generic Prices, Fails to Gain Support on Five Generic Price Ranges
December 9, 2013
- Survey Finds that 1 in 4 MRs Still Smoke; Board Member of JSTC Calls Finding “Extremely Disappointing”
November 15, 2013
- JPA Express Deep Regrets over Decision on Lifting Online Sales Ban of OTC Drugs
November 11, 2013
- Mr Shirakawa of Kenporen Calls for New Look at Range of Drugs Eligible for Premium for New Drug Development
November 11, 2013
- Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads
November 5, 2013
- JPMA Issues “Severe Warning” to MTPC for Violation of PAL Related to Medway Injection
November 1, 2013
- PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
- Keizai Doyukai Recommends Measures to Ensure Adequate Funding for Proposed Japanese NIH
October 31, 2013
- Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
- Medwatcher Japan Calls for Legislation to Regulate Clinical Research in Wake of Diovan Scandal
October 28, 2013
- JPMA to Consider Information Disclosure on Provision of Labor to Research Institutes in Response to Diovan Scandal
October 28, 2013
- JMA Vice Pres. Nakagawa to Be Reinstated as CSIMC Member
October 25, 2013
- No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
- JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
- Japan Self-Medication Industry’s Request Letter to Health Minister Factually Incorrect: JMA Exec
October 10, 2013
- Removal of JMA, JPA Members from OTC Drug Review Council, Open Discussion Would Be Difficult, Says JMA Exec
October 9, 2013
- Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
- Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…